Historically, PI3K has been a major therapeutic target in cancer treatment, with extensive research exploring dual PI3K/mTOR inhibitors, pan‐PI3K inhibitors, and p110a‐specific inhibitors in various types of cancers with both wild‐type and mutant PIK3CA.3, 4. This evidence concerns the gene MTOR and cancer.